Navigation Links
Adeona to Host Investor Day on Zinc Deficiency in Alzheimer's Disease
Date:1/18/2011

ANN ARBOR, Mich., Jan. 18, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that it will host an Alzheimer's disease-focused Investor Day on Tuesday, February 8, 2011 from 3:00-5:00 P.M. (EST) at the Kensington Court Hotel in Ann Arbor, Michigan. Headquartered in Ann Arbor, Adeona's management team welcomes shareholders, potential investors and interested parties to join them for this scientific and corporate update of the Company.

Keynote speaker, George J. Brewer, M.D., Chairman of Adeona's Scientific Advisory Board and the Morton S. and Henrietta Sellner Emeritus Professor of Human Genetics and Internal Medicine at the University of Michigan, will provide a scientific overview of the roles zinc deficiency and copper toxicity play in patients with Alzheimer's disease and mild cognitive impairment. After the scientific update, James S. Kuo, M.D., M.B.A.., Adeona's Chairman and CEO, will provide an investor update that includes the Company's near-term plans for its zinc-based therapy for Alzheimer's disease and mild cognitive impairment that is being developed as a prescription medical food. The webcast of these presentations will be accessible via the event section on the home page of Adeona's website at www.adeonapharma.com.

Adeona's management team will greet guests during a reception from 3:00-3:45 P.M., with the scientific and corporate presentations to follow. Attendance at Adeona's Investor Day is limited due to seating availability. People interested in registering to attend should contact the Company by email at investorday@adeonapharma.com or by phone at (734) 332-7800.

The Kensington Court Hotel is located near I-94 and South State Street (Exit #177) along the Briarwood Shopping Mall circle, only 2.5 miles from downtown Ann Arbor and the University of Michigan, and 25 miles from Detroit Metropolitan Airport. The hotel address is: 610 Hilton Blvd., Ann Arbor, MI. 48108.

About Adeona Pharmaceuticals, Inc.

Adeona is a pharmaceutical company developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Currently, Adeona is developing the following product candidates: a prescription medical food for Alzheimer's disease, and drugs for multiple sclerosis, fibromyalgia, rheumatoid arthritis and age-related macular degeneration. For more information, please visit Adeona's website at www.adeonapharma.com.

This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the timing and results of our clinical study and our ability to successfully develop products with superior benefits. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, a failure of our clinical  trials to be completed on time or to achieve desired results, a failure of our clinical reference laboratory to continue to grow and achieve revenue or a failure by us or our strategic partners to successfully commercialize products and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2009 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.


'/>"/>
SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Adeona to Present at OneMedForum San Francisco 2011 Conference
2. Adeona Acquires Access to Clinical Data Supporting Oral Zinc for Prevention of Infections in the Elderly
3. Adeona Announces Third Quarter 2010 Financial Results and Achievements
4. Adeona to Hold Annual Shareholder Meeting
5. Adeona CEO to Provide Keynote Address at the 2010 MichBio Expo & Conference Emerging Biosciences Showcase
6. Adeona Announces Five Scientific Publications on Role of Copper Toxicity and Zinc Deficiency in Alzheimers Disease and Cognitive Decline
7. Adeona Announces Second Quarter 2010 Profitability and Achievements
8. Adeona Completes Equity Financing and Provides Alzheimers Disease Clinical Study Update
9. Adeona Announces HartLab Expansion Into Microbiology Testing Services
10. NeoStem to Present at Two Investor Conferences in San Francisco on Wednesday, January 12, 2011
11. Watson to Host Investor Day on January 21 in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Feb. 9, 2016  Jazz Pharmaceuticals plc (Nasdaq: ... 2015 fourth quarter and full year financial results on ... financial markets.  Company management will host a live audio ... p.m. GMT to discuss fourth quarter and full year ... update and guidance for 2016 financial results. ...
(Date:2/9/2016)... -- Amarantus BioScience Holdings, Inc. (OTCQB: ... Regenerative Medicine, Neurology and Orphan Diseases, today announced that ... Capital Group,s 2016 Disruptive Growth & Healthcare Conference which ... New York City . The Company,s presentation will ... pm by Gerald E. Commissiong , President & ...
(Date:2/9/2016)... "Global Blood Monitoring & Cardiac Monitoring Devices Market Assessment & Forecast: ... global market for blood monitoring & cardiac monitoring devices was valued ... US$ 24,830.1 million by 2019 at a CAGR of 6.8% from ... Europe , Asia-Pacific , ... Africa . The three major factors determining growth of ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... February is Heart Awareness ... Rate Variability scans throughout the month to the American Heart Association, New Mexico chapter. ... signs of heart disease and Health Quest’s INSiGHT Pulse Wave Profiler utilizes a non-invasive ...
(Date:2/9/2016)... ... February 09, 2016 , ... A new study ... rates and Medicare rates for a variety of medical services in Illinois as ... of the 2015 Fee Schedule Rates in Illinois, are professional medical services, ...
(Date:2/9/2016)... California (PRWEB) , ... February ... ... automated print and e-book publishing software, in partnership with Snowfall4pod Digital, creators ... – a comprehensive book publishing, content management, global distribution and print-on-demand network. ...
(Date:2/9/2016)... ... February 09, 2016 , ... Establishment Labs, a global breast implant ... to the company´s Board of Directors. , “We are honored to welcome ... exceptional entrepreneur.” said Juan Jose Chacon Quiros, CEO of Establishment Labs. "David’s knowledge and ...
(Date:2/9/2016)... ... ... Journal of Pain Research has published the commentary “ Terminology of chronic ... John F. Peppin says “Terminology matters, yet little attention has been paid to the ... pain’ and ‘chronic non-cancer pain’ are replete in the literature; however, the distinction here ...
Breaking Medicine News(10 mins):